Government pledges £5bn for health R&D in the UK

We still need clarity on how the government will fund institutions like the MHRA and NICE, but the measures to boost investment in science and research in the UK announced by ... This funding is part of a wider £5.9bn capital investment in the UK’s

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

The SPAC is sponsored by Foresite Capital, a healthcare and life sciences investment firm based in the US. ... Most of the money raised will come from the SPAC itself, with approximately $75m to be raised through a private round with backers including

Lucid Group acquires strategic brand consultants DiD

The DiD acquisition is Lucid Group’s first with backing from its new investment partner Intermediate Capital Group (ICG), previously announced in March.

Nordic Capital acquires ADVANZ PHARMA for $846m

Cidron Aida Bidco, a subsidiary of private equity investor Nordic Capital, has completed its acquisition of speciality pharma company ADVANZ PHARMA. ... Nordic Capital will be pivotal in helping the business through both its deep sector expertise and

Sanofi pays $160m upfront to acquire Tidal Therapeutics

It received seed funding from Mission BioCapital, which was joined by RA Capital, New Enterprise Associates, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy, MRL Ventures and

The changing nature of approvals – what does the future hold?

High-profile disinvestments include those by Pfizer and Eli Lilly. However, Pfizer has since announced that, together with investment firm Bain Capital, it has created a new drug company called Cerevel ... Regulatory processes in Mainland China have

European biotech: a new generation of leaders emerges

This include specialist venture capital firms, which are upping their investment in the region, which is seen as underdeveloped compared to the sometime overheated Massachusetts and California biotech markets. ... As venture capital (VC) investors,

Biopharma's Future: Made in China

to encourage a home-grown pharma industry, as well as investment from multinational giant. ... Money flowing into Europe. Meanwhile, just as multinationals are increasing their investments in China, there is also a huge amount of investment capital

Drug pricing

European venture funding for the life science sector

The greater risk - given the inelasticity of the supply of R&D to the sudden increase in capital - is a lowering of the quality bar as marginal companies obtain investment. ... Keeping the bar high. To guard against this risk, it is essential that

Anish Mehta appointed CEO of new women's health business

Will head up the former Teva portoflio CVC Capital Partners recently acquired. ... London-based investment firm CVC Capital Partners has appointed Anish Mehta as chief executive officer of the international women’s health assets portfolio it acquired

David Horn Solomon takes the helm of Akari Therapeutics

Sanofi.”. His other roles have included CEO at Bionor Pharma and most recently he was at Nordic healthcare investment group Sund Capital where he was a managing partner.

IGEM Therapeutics appoints Dr Tim Wilson as CEO

has raised £2m from Epidarex Capital, in order to progress its pipeline of IgE antibody drug candidates. ... Wilson has over 28 years’ experience in the life sciences sector, ranging from venture capital and start-ups to investment banking and equity

BMS appoints three independent directors

Samuels also brings considerable business and operational experience to the position, with a particular expertise in economics, capital markets and investment decision-making. ... He currently serves as a director at Perrigo Company and Stamps.com, and

Dr Stephen Hoffman joins Bicycle Therapeutics

Dr Hoffman brings 30 years of experience in the pharmaceutical and financial industries to the biotech, currently serving as a senior advisor to PDL BioPharma and president of 10x Capital, an ... investment management firm.

GHO Capital Acquires Genesis Research

The Partners at GHO Capital said: “The investment in Genesis Research follows years of work internally to identify market leading platforms with ambitious management teams in RWE and HEOR. ... About GHO Capital. Global Healthcare Opportunities, or GHO

Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners

MAT is excited to officially announce a minority investment from Silversmith Capital Partners. ... that drive decision-making across the product lifecycle, today announced a $30 million minority investment from  Silversmith Capital Partners, a

Lucid Group acquires US-based strategic brand consultants DiD

This is Lucid Group’s first acquisition backed by its new investment partner Intermediate Capital Group (ICG) – a leading global alternative asset manager.

LUCID GROUP PARTNERS WITH NEW INVESTOR ICG

Lucid Group has secured a new investment from Intermediate Capital Group (ICG) to support its continued ambition to build a global business that delivers life transforming value for everyone. ... ICG brings deep healthcare sector expertise, a global

Newcells Biotech secures over £5m for 3D tissue models

Newcells Biotech have received multi-million investment to develop their pioneering 3D tissue models. ... The funding comes from two existing backers. Mercia has invested from its Northern Venture Capital Trust (VCT) and Enterprise Investment Scheme (EIS)